Technical Name | Discoverydevelopment of novel anti-diabetic drug candidate DBPR211 by antagonizing peripheral CB1 receptors | ||
---|---|---|---|
Project Operator | National Health Research Institutes | ||
Project Host | - | ||
Summary | DBPR211 is the second generation of CB1 receptor antagonist with peripheral distribution to avoid undesirable central CB1 receptor-induced psychiatric effects as commonly seen in the first generation of CB1 antagonists. DBPR211 is potentselective,it exhibits satisfactory efficacy, pharmacokinetic properties,can be orally absorbed. In obesediabetic mouse models, DBPR211 significa |
||
Scientific Breakthrough | - |
||
Industrial Applicability | - |
||
Keyword |